In summary, these studies established new concepts for the Ab-based treatment, such as the Ab-IL2, Ab–IFNβ, and Ab–LIGHT fusion proteins, which stimulate or augment the tumor-specific CTL responses to deal with Ab resistance and relapse more effectively. The gene discussed is IL2; the disease is neoplasm.